VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS)

Multiple Sclerosis Clinical Trial

— VIRTUAL-MS  

Official title:

Virtual Versus Usual In-office Care for Multiple Sclerosis: A Randomized Trial (VIRTUAL-MS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05660187
• Other study ID #: 1R01NR020323-01A1
• Status: Recruiting
• Phase: N/A
• Start date: March 31, 2023
• Est. completion date: June 2027

Study information

• Verified date: April 2024
• Source: The Cleveland Clinic
• Contact: Meredith Dever, MPH
• Phone: 216 444-5441
• Email: deverm[@]ccf.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current standard of outpatient MS care depends on in-clinic visits, but MS patients face many barriers to accessing this care. These barriers include those resulting from the disease itself, such as physical limitations, driving restrictions and financial limitations, and they are further compounded by an overall shortage of neurologists. Furthermore, MS care has a significant economic impact, with the estimated indirect and direct costs for treating MS in the US estimated to be > $85.4 billion. Therefore, there is a need to improve access to and reduce cost of MS care, and telehealth is a potential solution. The VIRTUAL-MS study has been designed to evaluate the impact of telehealth care on MS clinical outcomes, costs, and satisfaction compared to in-person care. Additionally, the study aims to evaluate facilitators and barriers to telehealth use to inform widespread implementation.

Description:

The VIRTUAL-MS study aims to evaluate the impact of telehealth on MS care. The study will conduct a 24 month randomized controlled clinical trial at two Centers (Cleveland Clinic and University of California San Francisco) and will enroll 60 adult people with MS per Center with a recent diagnosis of MS. Participants will be randomized 1:1 to receive follow-up MS care via scheduled telehealth, or standard in-clinic, visits. All participants will have in-person visits at baseline and 24 months with in-person study visit including clinical assessments, patient reported outcomes, and medical history review. All participants will have clinical visits with their neurology clinician every 6 months (months 6, 12, and 18) via in-person or telehealth per randomized arm.

The primary objective of this study is to determine if MS care delivered via telehealth is non-inferior compared to in-clinic MS care as measured by worsening in one of the Multiple Sclerosis Functional Composite (MSFC) components at Month 24.

The secondary objectives of this study include the following:

• To determine if MS care delivered via telehealth has superior patient satisfaction compared to in-person MS care as measured by baseline to 24 month change in PSQ-18.

• To determine if MS care delivered via telehealth is more cost-effective than MS care delivered via in-person visits as measured by total non-medication costs over 24 months.

The researchers will also explore other clinical outcomes, treatment adherence, digital outcomes, patient experience, and clinician experience.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: June 2027
• Est. primary completion date: June 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ages =18

2. MS diagnosis within 12 months of randomization by 2017 McDonald Criteria.

3. Confirmatory MRI within 6 months prior to randomization.

4. Access to either mobile device, laptop or PC with internet connection to be able to conduct virtual visits

5. Participant's neurologist and/or advanced practice provider are participating in the study

Exclusion Criteria:

1. Clinically relevant condition that, in the opinion of the PI, could preclude participation in the study (e.g. neutropenia or wound care requiring frequent monitoring)

2. Inability to provide informed consent

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Other:
• Multiple Sclerosis Clinical Care Delivery via telehealth
Intervention includes clinical care delivered via telehealth
• Multiple Sclerosis Clinical Care Delivery via standard in clinic visits
Intervention includes clinical care delivered via standard in clinic visits

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio
United States	University of California San Francisco	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
The Cleveland Clinic	University of California, San Francisco, University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with disability progression	The primary outcome will be disability worsening in one of the Multiple Sclerosis Functional Composite components at 24 months. Worsening is defined as 20% worsening in Timed 25 foot walking speed (T25FW), 20% worsening in the 9 hole peg test (9HPT), 20% worsening in Low Contrast Letter Acuity (LCLA) or a 4 point decrease in the Symbol Digit Modalities Test (SDMT).	Baseline to 24 months
Secondary	Change in Patient Satisfaction Questionnaire Short Form (PSQ-18)	The secondary outcome will assess patient and clinical care team satisfaction via the Patient Satisfaction Questionnaire Short Form (PSQ-18) short form.; Minimum value is 1 and maximum value is 5 for each question, where 5 means a better outcome.	Baseline to 24 months
Secondary	Compare major healthcare costs	The secondary outcome will compare major healthcare costs as measured by total non-medication costs.	Baseline to 24 months